Human Genome last week announced favorable phase I clinical data about the safety and tolerability of a drug to fight anthrax infections.

FORBES

Authorities should reconsider whether herbal medicines, as conventional drugs, need regulation and should be tested for safety, tolerability and efficacy for the benefit of our patients.

BBC: Herbal remedy 'interferes with treatments'

The day before the opening today of the ASH conference in Atlanta, TG Therapeitics announced it has initiated a phase 1 and 2 clinical trials to evaluate the safety, tolerability and efficacy of its product, TG-1101, a novel third-generation anti-CD20 monoclonal antibody, in combination with Revilimid for patients with relapsed or refractory B-cell lymphoid malignancies who were previously treated with anti-CD20 antibody therapy.

FORBES: Don't Be Surprised If Underpriced Small-Cap Biotechs Catch Investors' Eye Once Again